Dai Chihara
UT MD Anderson Cancer Center · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dai Chihara as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07917832 · Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaM.D. Anderson Cancer Center · not yet recruiting · Multi Center, Phase 2, Golcadomide · principal investigator
- N/ANCT07829445 · PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCLM.D. Anderson Cancer Center · recruiting · LBCL, Comprehensive Genomic, Precision Treatment · principal investigator
- Ph2NCT07783594 · Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaM.D. Anderson Cancer Center · not yet recruiting · Randomized, Phase 2, Epcoritamab · principal investigator
- Ph2NCT07316010 · Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center · recruiting · Large B-cell Lymphoma · principal investigator
- Ph2NCT06670105 · A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center · withdrawn · B-cell Lymphoma · principal investigator
- Ph2NCT06563505 · A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaM.D. Anderson Cancer Center · recruiting · Lymphoma · principal investigator
- Ph2NCT06108232 · Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaM.D. Anderson Cancer Center · recruiting · Follicular Lymphoma, Tumor · principal investigator
- Ph2NCT06045247 · Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaM.D. Anderson Cancer Center · recruiting · Large B-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:20 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.J Clin Oncol · 202090 citationsRCR 4.4
- Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.Br J Haematol · 201689 citationsRCR 2.8
- 75 citationsRCR 2.4
- 64 citationsRCR 3.5
- 64 citationsRCR 13.7
- A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.Blood Adv · 202346 citationsRCR 3.5
- Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Eur J Haematol · 201330 citationsRCR 0.9
- Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.Lancet Haematol · 202430 citationsRCR 4.6
- Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.Neuro Oncol · 201629 citationsRCR 1.1
- Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood Adv · 202126 citationsRCR 1.4